Billions of dollars are flowing into anti‑ageing biotechnology, reflecting a surge of investor confidence in the promise of extending healthy human lifespan. Yet the science behind manipulating ageing remains incomplete, and experts warn that the risks are only beginning to be understood.
The rapid influx of capital has spurred a wave of research into cellular senescence, telomere biology, and metabolic pathways that may slow or reverse age‑related decline. Venture capitalists and large pharmaceutical firms are funding a growing number of start‑ups that claim breakthroughs in longevity therapeutics.
Despite the enthusiasm, scientists caution that interventions targeting the ageing process could have unforeseen biological consequences. The long‑term safety and efficacy of such treatments are still under investigation, and the full spectrum of potential side effects is not yet known.
Industry optimism is tempered by regulatory uncertainty and the ethical questions surrounding life extension. While some view the investment as a step toward healthier, longer lives, others argue that a more measured approach is needed to avoid unintended harm.
As the anti‑ageing biotech sector expands, the balance between innovation and precaution will shape the future of longevity research and its impact on society.
<small>Source: Al Jazeera — read the original story there.</small>
